Positive News SentimentPositive NewsNYSE:GMED Globus Medical (GMED) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free GMED Stock Alerts $53.65 +0.59 (+1.11%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$52.77▼$53.9850-Day Range$51.15▼$56.5252-Week Range$43.38▼$62.88Volume764,336 shsAverage Volume1.18 million shsMarket Capitalization$7.26 billionP/E Ratio45.86Dividend YieldN/APrice Target$66.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Globus Medical alerts: Email Address Globus Medical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside23.6% Upside$66.33 Price TargetShort InterestBearish4.33% of Shares Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment1.65Based on 5 Articles This WeekInsider TradingSelling Shares$550,574 Sold Last QuarterProj. Earnings Growth21.93%From $2.69 to $3.28 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.75 out of 5 starsMedical Sector25th out of 938 stocksSurgical & Medical Instruments Industry1st out of 97 stocks 2.3 Analyst's Opinion Consensus RatingGlobus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $66.33, Globus Medical has a forecasted upside of 23.6% from its current price of $53.65.Amount of Analyst CoverageGlobus Medical has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.33% of the outstanding shares of Globus Medical have been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Globus Medical has recently increased by 2.27%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Globus Medical is -0.93. Previous Next 3.1 News and Social Media Coverage News SentimentGlobus Medical has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Globus Medical this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $550,574.00 in company stock.Percentage Held by Insiders24.30% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.16% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Globus Medical are expected to grow by 21.93% in the coming year, from $2.69 to $3.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 45.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 45.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 240.03.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.52. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Globus Medical Stock (NYSE:GMED)Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Read More GMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GMED Stock News HeadlinesMarch 20, 2024 | insidertrades.comGlobus Medical, Inc. (NYSE:GMED) Director Sells $550,574.10 in StockMarch 24, 2024 | investorplace.comFrom Six Figures to Seven: 3 Robotics Stocks Set to Make MillionairesMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 19, 2024 | msn.com1 'Strong Buy' Growth Stock Wall Street Expects to Soar Around 70%March 19, 2024 | americanbankingnews.comGlobus Medical (NYSE:GMED) Upgraded by BTIG Research to BuyMarch 18, 2024 | theglobeandmail.comStrength in Technology Stocks Leads the Broader Market HigherMarch 18, 2024 | theglobeandmail.comStocks Rally on Strength in Technology StocksMarch 18, 2024 | americanbankingnews.comGlobus Medical, Inc. (NYSE:GMED) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 16, 2024 | nasdaq.comGlobus Medical (GMED) Shares Cross Below 200 DMAMarch 16, 2024 | finance.yahoo.comGMED Apr 2024 57.500 callMarch 16, 2024 | finance.yahoo.comGMED Apr 2024 50.000 putFebruary 27, 2024 | seekingalpha.comGlobus Medical Q4: Greater Dis-Synergies Hold Back The StockFebruary 25, 2024 | msn.comNeedham sees orthopedics market slowing; favors Enovis, Paragon 28February 22, 2024 | finance.yahoo.comGlobus Medical Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 21, 2024 | realmoney.thestreet.comGlobus Medical price target raised by $3 at Stifel, here's whyFebruary 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Universal Health (UHS) and RAPT Therapeutics (RAPT)February 21, 2024 | finance.yahoo.comGlobus Medical, Inc. (NYSE:GMED) Q4 2023 Earnings Call TranscriptFebruary 21, 2024 | finance.yahoo.comCompared to Estimates, Globus Medical (GMED) Q4 Earnings: A Look at Key MetricsFebruary 21, 2024 | fool.comGlobus Medical (GMED) Q4 2023 Earnings Call TranscriptFebruary 20, 2024 | benzinga.comGlobus Medical: Q4 Earnings InsightsFebruary 20, 2024 | seekingalpha.comGlobus Medical Non-GAAP EPS of $0.60 misses by $0.01, revenue of $616.53M beats by $8.36MFebruary 20, 2024 | markets.businessinsider.comGlobus Medical Reports Fourth Quarter and Full Year 2023 ResultsFebruary 20, 2024 | finance.yahoo.comGlobus Medical Inc (GMED) Posts Record Sales Amid NuVasive Merger, Despite Net Income DipFebruary 20, 2024 | globenewswire.comGlobus Medical Reports Fourth Quarter and Full Year 2023 ResultsFebruary 20, 2024 | ca.finance.yahoo.comPRCT Mar 2024 60.000 callFebruary 19, 2024 | msn.comGlobus Medical Q4 2023 Earnings PreviewSee More Headlines Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNYSE:GMED CUSIP37957720 CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees5,000Year FoundedN/APrice Target and Rating Average Stock Price Target$66.33 High Stock Price Target$86.00 Low Stock Price Target$53.00 Potential Upside/Downside+23.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.17 Trailing P/E Ratio45.86 Forward P/E Ratio19.94 P/E Growth1.52Net Income$122.87 million Net Margins7.83% Pretax Margin10.55% Return on Equity8.82% Return on Assets7.20% Debt Debt-to-Equity Ratio0.10 Current Ratio4.88 Quick Ratio2.72 Sales & Book Value Annual Sales$1.02 billion Price / Sales7.12 Cash Flow$3.75 per share Price / Cash Flow14.31 Book Value$29.32 per share Price / Book1.83Miscellaneous Outstanding Shares135,370,000Free Float102,477,000Market Cap$7.26 billion OptionableOptionable Beta1.09 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. David C. Paul (Age 57)Co-Founder & Executive Chairman Comp: $1.09MMr. Daniel T. Scavilla (Age 59)President, CEO & Director Comp: $1.37MMr. Keith W. Pfeil (Age 44)CFO & COO Comp: $675.89kMs. Kelly G. Huller Esq. (Age 52)Senior VP, General Counsel & Secretary Comp: $543.24kMr. Brian J. Kearns (Age 57)Senior Vice President of Business Development & Investor Relations Key CompetitorsTeleflexNYSE:TFXIntegra LifeSciencesNASDAQ:IARTAlphatecNASDAQ:ATECBaxter InternationalNYSE:BAXInspire Medical SystemsNYSE:INSPView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Sold 38,845 shares on 3/27/2024Ownership: 0.014%HighPoint Advisor Group LLCBought 3,930 shares on 3/26/2024Ownership: 0.003%Quadrature Capital LtdSold 30,795 shares on 3/25/2024Ownership: 0.027%PNC Financial Services Group Inc.Sold 12,611 shares on 3/22/2024Ownership: 0.007%Leslie V NorwalkSold 10,590 sharesTotal: $550,574.10 ($51.99/share)View All Insider TransactionsView All Institutional Transactions GMED Stock Analysis - Frequently Asked Questions Should I buy or sell Globus Medical stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GMED shares. View GMED analyst ratings or view top-rated stocks. What is Globus Medical's stock price target for 2024? 9 Wall Street analysts have issued 1 year price objectives for Globus Medical's stock. Their GMED share price targets range from $53.00 to $86.00. On average, they predict the company's share price to reach $66.33 in the next twelve months. This suggests a possible upside of 23.6% from the stock's current price. View analysts price targets for GMED or view top-rated stocks among Wall Street analysts. How have GMED shares performed in 2024? Globus Medical's stock was trading at $53.29 at the beginning of the year. Since then, GMED stock has increased by 0.7% and is now trading at $53.65. View the best growth stocks for 2024 here. Are investors shorting Globus Medical? Globus Medical saw a increase in short interest in February. As of February 15th, there was short interest totaling 5,780,000 shares, an increase of 8.6% from the January 31st total of 5,320,000 shares. Based on an average daily volume of 1,220,000 shares, the short-interest ratio is currently 4.7 days. View Globus Medical's Short Interest. When is Globus Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our GMED earnings forecast. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings data on Tuesday, February, 20th. The medical device company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.01. The medical device company earned $616.53 million during the quarter, compared to analysts' expectations of $608.21 million. Globus Medical had a net margin of 7.83% and a trailing twelve-month return on equity of 8.82%. The company's quarterly revenue was up 124.6% on a year-over-year basis. During the same period last year, the firm earned $0.59 earnings per share. What ETFs hold Globus Medical's stock? ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Health Care Equipment ETF (XHE) and First Trust Health Care AlphaDEX Fund (FXH).iShares U.S. Medical Devices ETF (IHI). What guidance has Globus Medical issued on next quarter's earnings? Globus Medical updated its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share guidance of 2.680-2.700 for the period, compared to the consensus EPS estimate of 2.690. The company issued revenue guidance of $2.5 billion-$2.5 billion, compared to the consensus revenue estimate of $2.5 billion. What is David Demski's approval rating as Globus Medical's CEO? 47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA). Who are Globus Medical's major shareholders? Globus Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.18%), Vanguard Group Inc. (8.33%), Wellington Management Group LLP (2.15%), Dimensional Fund Advisors LP (1.32%), Norges Bank (1.30%) and GW&K Investment Management LLC (1.28%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Leslie V Norwalk. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:GMED) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.